Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASARE: 4P-004 in Knee Osteoarthritis
NCT05419856Phase 1Completed
- Sponsor
- 4Moving Biotech
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liraglutide in knee osteoarthritis (OA) (5 arms), sponsored by 4Moving Biotech. Primary endpoint: Safety and Tolerability of Single IA Administration of 4P-004. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05419856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419856.